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Abstract
Background: Informed consent is the backbone of a clinical trial. In children this is given by their
parents. There have been many studies in the neonatal population but little is known about the
views of the parents of infants and young children from within the United Kingdom. The objectives
of this study were to assess what motivates parents to consent to a randomised clinical trial (RCT),
their feelings on consent and participation and the factors that would influence their decision to
take part in a future study.
Methods: The setting was a multi-centre randomised but non-blinded equivalence trial of oral
versus intravenous (IV) treatment for community acquired pneumonia in previously well children
aged 6 months to 16 years in the UK (PIVOT Study). Parents were sent a postal questionnaire at
the end of the study which included open and closed-ended questions. Fishers Exact Test was used
to analyse associations in non parametric categorical data.
Results: 243 children were recruited into the PIVOT study. Of a possible 235, 136 questionnaires
were returned (response rate 59%). Of those questionnaires returned; 98% of parents
remembered consenting, 95% felt they were given enough time to make their decision and 96% felt
they received enough information. Major reasons for participation were benefit to other children
in the future 31%, contribution to science 27%, benefit to their own child 18%. Most parents (85%)
did not feel obliged to participate. 62% felt there was an advantage to taking part and 18% felt there
was a disadvantage. 91% of parents said they would take part in a similar study in the future, stating
influences on their decision being benefit to their own child (91%) and benefit to all children (89%).
Conclusion:  The major motivation in parents consenting for their previously well child to
participate in an RCT of therapy for an acute medical illness was to increase medical knowledge in
the future. Most saw an advantage in taking part in the trial and did not feel obliged to participate.
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Background
Research in a child is different to that in adults. Informed
consent is essential for recruitment into a randomised
controlled trial. The informed consent process is under-
taken in the majority of paediatric trials by the child's par-
ent. It has been found that a child's ability to assent or
consent to research under the age of 9 years is limited [1].
Recruitment is said to be difficult within paediatric trials
and quoted as being the single most difficult problem to
overcome; leading to delays, increased costs and failure to
complete drug trials [2-4]. Therefore understanding why a
parent allows their child to participate in research is essen-
tial in taking forward paediatric research in the future.
There have been several studies on the consent process
and the information retained by parents following this
process. The majority of work within the United Kingdom
has centred on neonatal research[5,6]. A study in the
Netherlands[7] of a randomised placebo controlled trial
of ibuprofen syrup to prevent febrile convulsions found
that, within the infant age group, the major factors in par-
ents granting approval were contribution to clinical sci-
ence (51%) and benefit to the child (32%). A quarter of
parents felt obliged to participate and over half (60%)
said they would be willing to participate in a similar study
in the future.
Based on the information provided by the clinician, par-
ents decide whether or not to permit their child to partic-
ipate in that study. Understanding the parent's major
thoughts and motivations at this time may help improve
this process and increase the numbers participating in
future studies. This present study aims to look at a group
of parents approached for consent in a multi-centre ran-
domised controlled trial of previously well infants and
children presenting with pneumonia, within the United
Kingdom[8]. The aim was to see if the motives of British
parents are similar to those seen in Europe, to assess
parental views on the informed consent process, the infor-
mation provided and their reasons for taking part in the
study. Their willingness to participate in future research
was also examined.
Methods
The Trial
A multicentre randomised controlled equivalence trial
compared oral amoxicillin and IV benzylpenicillin for
community acquired pneumonia in children in hospital
(PIVOT)[8]. It was undertaken at eight hospitals in Eng-
land. Children aged 6 months to 16 years with fever, res-
piratory symptoms or signs and radiologically confirmed
pneumonia were eligible. 245 children were randomised
to either oral amoxicillin or IV benzylpenicillin. The pri-
mary outcome measure was time for the temperature to be
less than 38°C for 24 continuous hours and oxygen
requirement to cease.
Informed consent procedure
Once the diagnosis had been made the parents were
approached regarding the trial. Written parent informa-
tion was provided at the child's diagnosis and the parent
was then asked to reach a decision on participation prior
to the start of treatment. Information sheets were pro-
vided for children aged 7 years and over. Older children
and teenagers were asked for their assent and could com-
plete the consent form as well as their parents. Unlike
studies of children's cancer, for example, when parents
may have 24 hrs to reflect, consent had to be decided rap-
idly as treatment could not be deferred. All children had
blood tests performed and those in the intravenous group
had a cannula left in situ for antibiotics. If the parents
declined consent and volunteered a reason, this was
recorded on a separate data collection form anonymously.
The Questionnaire
Ethical approval was obtained from the Southern Derby-
shire Local Research Ethics Committee. A parental ques-
tionnaire was designed to try and elicit parental views on
consent and participation in research. The questionnaire
included both structured and semi-structured questions as
detailed below (Figure 1). This was kept to two sides of A4
paper to try and encourage return. Because of this the
questionnaire was limited to include the primary question
on reason for participation. Demographic details on the
person completing the questionnaire were not collected.
The themes for reasons for participation were taken from
a previous questionnaire based study conducted with par-
ents in the Netherlands[7] as these had already been vali-
dated in a European population. Parents were asked to
agree or disagree with a list of reasons that might have
influenced their decision to enrol their child in the study,
such as benefit to all children in the future (Figure 1-
Questionnaire). Open free text questions were posed for
the main reason for participation and any advantages or
disadvantages they experienced from the study. The ques-
tionnaire was not piloted as there were no parents availa-
ble in hospital who had taken part in research studies at
the time of its development.
The anonymous questionnaire was mailed to all parents
in July 2004 after the two-year recruitment period had fin-
ished. A stamped addressed envelope was included. It was
felt not to be appropriate to send questionnaires to the
two parents who withdrew during the study. The ques-
tionnaire was re-mailed in September 2004. A returned
completed questionnaire was taken as consent by the par-
ent. Completed questionnaires were coded and analysed
using the SPSS statistical package. Fishers Exact Test wasBMC Pediatrics 2007, 7:12 http://www.biomedcentral.com/1471-2431/7/12
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Original Questionnaire Figure 1
Original Questionnaire.
Dear Parents, 
Many thanks for allowing your child to participate in the PIVOT study of children with pneumonia. We are looking at the reasons why parents 
participate in studies and would appreciate if you could complete this short questionnaire. 
Thank you for your time. 
 
1.  What was your major reason for taking part in the study?  
………………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………….. 
2.  In deciding to take part in the study, which for the following influenced your decision?     (please tick)                                                    
 Agree  Disagree 
- Contribution to  science     
- Benefit for your child     
- Benefit for other children in the future     
- Give something in return for the care of our child     
- Doctor asked us     
- No reason     
 
3.  Did you feel obliged to participate?   (please circle)      YES     NO 
.  Did you feel there were any advantages to taking part?        YES    NO 
Please give any reasons: 
………………………………………………………………………………………………………………………………………………………                                    
………………………………………………………………………………………….…………………………………………………………… 
5.  Did you feel there were any disadvantages to taking part?    YES    NO 
Please give any reasons. 
…………………………………………………………………………………….…………………………………………………………………
………………………………………………………………………………………………………………………………………………...
  
6.  Would you take part in a similar study again?  (please circle)     YES     NO 
 
7. Which of the following would influence your decision to take part in future studies:(please tick)                                                    
 Agree  Disagree 
- Contribution to clinical science     
-  Benefit for your child     
-  Benefit for other children in the future     
- Received extra medical care and support     
- No benefit for your child     
- The extra time and work involved     
- The uncertainty of which treatment will be received     
- Involved more blood tests     
- It would depend on the study     
- No reason     
          
8.  Do you remember consenting for your child to take part?  YES    NO  (please circle) 
9.  Did you feel you had enough time to make your decision?  YES      NO 
10. Did you feel you received sufficient information?    YES    NO 
Thank you for taking the time to complete this short questionnaire. Please return in the stamped addressed envelope provided 
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used to analyse association in non parametric categorical
data.
Results
Demographics
243 parents were identified from the PIVOT study after
the two year recruitment had finished. Eight addresses
were incorrect and therefore questionnaires were unable
to be delivered. 136 questionnaires were returned (30
after the re mailing), a response rate of 59%. The response
rate was not affected by time, with a constant response
rate across the whole duration of the study. The median
age of the child for which parents responded to the ques-
tionnaire was 2.0 years (range 6 months to 12 years and 4
months) compared to a median age of 2.4 years in the
overall study. The questionnaire did not specify which
parent was filling in the questionnaire. The PIVOT study
had a 69% consent rate and details on the socioeconomic
status of the families within the study or the questionnaire
were not collected.
Reasons for participation
The major reason given by parents for taking part in the
study was benefit to all children in the future and a contri-
bution to science in 57% (Figure 2). Only 18% said that
the major reason they took part was benefit to their own
child. Parents answered this question in their own words.
The remainder stated that they participated because they
were asked by a doctor or that there was no reason not to.
When questioned directly on each theme, 96% agreed
that benefit to all children and 72% benefit to their own
child had influenced their decision to participate. 67%
said that they consented in order to give something in
return for care for their child and 63% because the doctors
asking had influenced their decision. This was not statisti-
cally influenced by the child's age.
Advantages and disadvantages of participation
Just under two thirds (62%) felt that there had been an
advantage to taking part in the study. Of those that
expressed an advantage, for over half (57.5%) this was
theoretical in giving knowledge for treatment of all chil-
dren in the future. The remainder felt the benefit was to
their own child including oral medication, quicker recov-
ery, more information given and closer monitoring.
24 parents (18%) felt that there had been a disadvantage
in participating. The disadvantages stated were the use of
needles (although it had been explained that both groups
would have blood tests as standard), delay in starting
treatment due to randomisation, anxiety that randomised
treatment would be less effective and having no choice
over treatment. Four parents felt their child had a poorer
recovery due to oral treatment (though this was not born
out in the overall results which showed equivalence of the
two treatments[8]). 18 parents (13%) said that they felt
obliged to take part and 9 (7%) felt that they would not
take part in a similar study in the future. 98% of parents
remembered consenting, 95% felt that they had enough
time to make their decision. 96% felt that they had
received enough information. These answers were not sta-
tistically influenced by the child's age or the time since
recruitment had taken place.
Future studies
Parents were asked which factors would influence their
decision to take part in a future study with their child. The
major factors were benefit to their own child (91%), ben-
efit to all children (89%) and contribution to medical sci-
ence (83%). Interestingly only 14% said they would not
take part if there was no benefit to their own child and
23% if it involved blood tests. The uncertainty of treat-
ment would influence just under a third of parents' deci-
sions but the majority (80%) said that it would depend on
the design of the trial.
If a parent expressed an advantage, 62% (p = 0.002), or
did not express a disadvantage, 81% (p = 0.05), then they
were statistically more likely to say that they would take
part in a similar study in the future. However 42 (84%) of
those parents who did not feel there was an advantage
would still take part in a similar future study. This was not
statistically influenced by the child's age.
The relationship between wanting to take part in a similar
study in the future was examined in relation to the views
expressed on motivations for future studies. Parents who
did not feel that 'benefit for other children in the future'
influenced their decision to participate were less likely to
participate again in the future (p = 0.045). If a parent felt
that they did not receive enough information (p = 0.053),
or have enough time to make their decisions (p = 0.004)
then they were statistically more likely to express a wish
not to participate in future studies. Randomisation to oral
or IV treatment did not make a difference to this decision
(p = 0.28).
Declined to participate
43 parents approached to participate in the PIVOT trial
declined for their child to take part. Of these 30 expressed
a reason to the clinician and these were collected anony-
mously. The majority (25) stated that they wanted a spe-
cific treatment for their child, either IV (20) or oral (5).
Many parents expressed a view that IV treatment was supe-
rior and therefore were unwilling to undergo randomisa-
tion. Of the remaining parents, two declined consent
because they did not want to participate in a trial, two
expressed that they were too distressed by their child's
admission to consider consenting and one declined con-
sent because of the paragraph on the consent form sayingBMC Pediatrics 2007, 7:12 http://www.biomedcentral.com/1471-2431/7/12
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that the ethics committee would have access to their
child's notes.
Discussion
In this study, of a general paediatric condition in the
childhood population in the UK, the major motivator for
the participation in clinical trials is for the good of all chil-
dren and the furthering of clinical science. This is a posi-
tive finding and good for future trial recruitment. It means
that if a trial is designed well with a clear clinical question
with which parents can identify, then they are likely to
consider taking part. As an important predictor of consent
this had previously been recognised in work carried out
on clinical anaesthesia and surgical studies in children[9].
This is reinforced in our results in that parents who felt
that they did not receive enough time to consider their
decision or receive enough information were statistically
less likely to wish to take part in future studies. The main
reason expressed by those parents who declined to con-
sent was the perception that one treatment was superior to
another. This may show a lack of understanding of the
information presented and this has been found to be
another important predictor of consent[9]. The PIVOT
study recruitment rate was 82% which was high compared
to that quoted in previous studies of 68% and 43%[10].
This may be related to the pragmatic nature of the trial
Main reason given by parents for their participation Figure 2
Main reason given by parents for their participation.
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and the fact that it did not ask for any extra blood taking
or immunisation, which have been quoted as reasons for
non-enrolment in other studies[10].
The attitudes of our British parents were very similar to
those seen in the previous Dutch study[7] with contribu-
tion to clinical science being the biggest motivator in both
groups. A more recent study[11] in France showed that the
possibility of receiving the most advanced treatments and
the confidence placed in the medical team were their
highest motivations for participation. Their population
were children treated for either a cancer or HIV infection.
The relatively high risk nature of these diseases is most
likely the reason for the difference between their results
and those seen in our own population. In a study con-
ducted in the United States[12] the importance of receiv-
ing the newest drugs, financial benefit, and free office
visits were highlighted. A statistical correlation was noted
between the importance of free medication and lower
family income. Financial incentives can be offered within
the USA; in the study above the mean compensation was
$570 per child recruited. This reflects the differences in the
health care systems between the USA and the UK, where
there is free access to health care. In our study, over two
thirds of our parents responded that giving something in
return for their care had influenced their decision to par-
ticipate.
One of the limitations of the present study, and the ques-
tionnaire method, is the response rate (59% in our current
study). This was lower than the previous Dutch study of
79%[7]. Of those who did not respond we do not know if
their views would be similar to those who were willing to
fill in the questionnaire. This may mean that we overesti-
mate the positive attitudes to this and future studies.
There would also have been a recall bias associated with
mailing the questionnaire to all parents at the end of the
study. Some parents may have been recruited to the trial
up to two years prior to the questionnaire being com-
pleted and therefore their recall would have been different
to those recruited in the last few months. There was how-
ever an equal spread of responses over the recruitment
period and the time since recruitment did not statistically
alter the responses to the questions of information, time
and remembering consent. Our results are based on the
responses to a single study, in a general paediatric condi-
tion, and thus the results may not be generalizable to
other studies that have different risk/benefit profiles.
Conclusion
This study has highlighted that the reasons that parents
consent for clinical trials in the United Kingdom is similar
to that seen in other European countries. Future work, ide-
ally within a multinational trial of the same disease pro-
file, to compare parental attitudes within different health
care systems would be interesting. The majority of parents
consent because they see the clinical need of the trials to
answer questions for the treatment of future children.
When financial incentives and cost of health care are
introduced this may change motives. It is important that
we understand the motivation of parents, within our own
populations and different disease profiles, with the intro-
duction of European legislation to ensure that all medi-
cines are studied in children and the challenges that it will
bring.
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